Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme

G Giovannoni; P A Brex; D Dhiraj; J Fullarton; M Freddi; B Rodgers-Gray; K Schmierer

doi:10.1177/2055217319893103

Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme

Mult Scler J Exp Transl Clin. 2019 Dec 5;5(4):2055217319893103. doi: 10.1177/2055217319893103. eCollection 2019 Oct-Dec.

Authors

G Giovannoni^{1

2}, P A Brex³, D Dhiraj⁴, J Fullarton⁵, M Freddi⁵, B Rodgers-Gray⁵, K Schmierer^{1

2}

Affiliations

¹ Blizard Institute, Barts, and The London School of Medicine and Dentistry, Queen Mary University London, UK.
² Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, UK.
³ King's College Hospital NHS Foundation Trust, UK.
⁴ Teva UK Limited, UK.
⁵ Strategen Limited, UK.

Abstract

Background: The UK Risk Sharing Scheme (RSS) provided information on the effect of first-line multiple sclerosis (MS) disease-modifying treatments on long-term disability.

Objective: The aim is to provide results specific to glatiramer acetate (GA; Copaxone®) from the final 10-year analysis of the RSS.

Methods: A Markov model was used to assess clinical effectiveness measured as Expanded Disability Status Scale (EDSS) progression and utility loss. Untreated patients from the British Columbia MS cohort (1980-1995) were used as a 'virtual comparator' group. A separate Markov model assessed cost-effectiveness, based on a 50-year time horizon (with a 50% treatment waning effect imposed at 10 years) and using NHS list price (£513.95 per 28 days). Results were expressed in quality-adjusted life years (QALYs).

Results: In total, 755 patients with relapsing-remitting MS (RRMS) received GA, with a mean follow-up of 7.1 (standard deviation 1.3) years. EDSS progression was reduced by 23% (progression ratio 76.7, 95% confidence interval [CI] 69.0-84.3) and utility loss by 39% (progression ratio 61.0, 95% CI 52.7-69.3) compared with no treatment. There was no persistent waning in GA treatment effect over time (EDSS: p = 0.093; utilities: p = 0.119). The cost per QALY was £17,841.

Conclusion: GA had a beneficial effect on long-term disability and was a cost-effective treatment for RRMS.

Keywords: Relapsing–remitting multiple sclerosis; disability; disease-modifying therapy; real-world evidence.